Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Increase in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 47,507 shares, a growth of 1,454.0% from the April 30th total of 3,057 shares. Based on an average daily volume of 651,410 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy”.

Daiichi Sankyo Trading Down 0.7%

OTCMKTS DSNKY traded down $0.11 during trading hours on Wednesday, hitting $16.81. The company’s stock had a trading volume of 196,924 shares, compared to its average volume of 312,341. The stock has a fifty day moving average of $17.47 and a 200 day moving average of $19.64. Daiichi Sankyo has a twelve month low of $15.56 and a twelve month high of $28.21. The firm has a market capitalization of $31.84 billion, a P/E ratio of 17.88, a PEG ratio of 1.21 and a beta of -0.25. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Equities research analysts forecast that Daiichi Sankyo will post 0.91 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.